Lipocine Inc.
LPCN
$2.11
$0.052.43%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -69.48% | 27.16% | -67.19% | -- | 595.09% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -69.48% | 27.16% | -67.19% | -- | 595.09% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -69.48% | 27.16% | -67.19% | -- | 595.09% |
| SG&A Expenses | 11.30% | 7.31% | 12.63% | -26.54% | -40.93% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.17% | 81.73% | 88.15% | 32.13% | -10.49% |
| Operating Income | -18.21% | -84.17% | -262.78% | -27.77% | 26.98% |
| Income Before Tax | -18.89% | -96.92% | -232.99% | -43.63% | 28.11% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -18.90% | -96.90% | -232.99% | -43.63% | 28.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.90% | -96.90% | -232.99% | -43.63% | 28.12% |
| EBIT | -18.21% | -84.17% | -262.78% | -27.77% | 26.98% |
| EBITDA | -18.40% | -84.84% | -260.19% | -27.65% | 27.28% |
| EPS Basic | 22.54% | -54.98% | -225.21% | -41.89% | 28.23% |
| Normalized Basic EPS | 22.55% | -54.98% | -225.16% | -41.92% | 28.21% |
| EPS Diluted | 22.35% | -54.40% | -233.61% | -33.88% | 28.23% |
| Normalized Diluted EPS | 22.55% | -54.98% | -233.01% | -41.92% | 28.21% |
| Average Basic Shares Outstanding | 53.53% | 27.04% | 6.23% | 1.22% | 0.15% |
| Average Diluted Shares Outstanding | 53.53% | 27.04% | -0.03% | 1.22% | 0.15% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |